CSIMarket


Inotiv Inc   (NOTV)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare


 

Inotiv Inc

NOTV's Financial Statements and Analysis



Inotiv Inc increased second quarter of 2024 net loss per share of $-1.86 compare to net loss per share of $-0.39 recorded in the same quarter a year ago a decrease compare to $-0.60 realized in previous quarter.


second quarter of 2024
Earnings Per Share Revenues
$ -1.86 $  119 Mill
$-1.47     $-32M     -21.41 %



Inotiv Inc 's Revenue fell by -21.41 % in second quarter of 2024 (Mar 31 2024) year on year, to $119 million and declined by -12.15 % sequentially.


Inotiv Inc is

More on NOTV's Income Statement



Inotiv Inc in the second quarter of 2024 recorded net loss of $-48.079 million, an increase from net loss of $-9.629 million in II. Quarter a year ago.

Sequentially net loss advanced

More on NOTV's Growth

Inotiv Inc Inventories
Inventories declined by -29.37 % to $45.41 million from II. Quarter a year ago, sequentially inventories fell by -10.34 %. NOTV's Cash flow In the second quarter of 2024 company's net cash flow was $11 million, capital expenditures grew by -16.84-58.30%, to $-7 millions compare to same quarter a year ago

More on NOTV's Cash flow Statement


Inotiv Inc does not pay out common stock dividend.

In trailing twelve-month period Inotiv Inc earned $ 1.27 cash per share, on a free-cash flow basis .

Book value fell by -18.70 % sequentially to $8.02 per share, -66.73% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ -6.91 per share from $ -5.45.

Company issued 0.07 million shares or 0.26 % in Mar 31 2024.


More on NOTV's Dividends

 Market Capitalization (Millions) 53
 Shares Outstanding (Millions) 26
 Total Debt (Millions $) 381
 Revenue (TTM) (Millions $) 553
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) -23
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Inotiv Inc does not pay out common stock dividend.

In trailing twelve-month period Inotiv Inc had $ 1.27 cash flow per share, on a free-cash flow basis .

Book value fell by -18.70 % sequentially to $8.02 per share, -66.73% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ -6.91 per share from $ -5.45.

Company issued 0.07 million shares or 0.26 % in Mar 31 2024.


More on NOTV's Balance Sheets

 Market Capitalization (Millions) 53
 Shares Outstanding (Millions) 26
 Total Debt (Millions $) 381
 Revenue (TTM) (Millions $) 553
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) -23
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Inotiv Inc Earnings

Inotiv Inc. Shockingly Reveals -21.41% Revenue Decline in Recent Financial Report

Inotiv, Inc., a prominent contract research organization specializing in nonclinical and analytical drug discovery and development services, recently reported their financial results for the fiscal interval ending March 31, 2024. The company experienced weak orders, which caused a rise in losses. Their net deficit per share increased to $-1.86 from $-0.39, while revenue fell by -21.41% to $119.04 million from $151.46 million compared to the previous year.
This decline in business is in stark contrast to the overall trend in the Medical Laboratories industry, which recorded a revenue improvement during the same period. Inotiv's revenue also deteriorated by -12.152% from $135.50 million in the previous qua...

Inotiv Inc takes strategic steps to enhance profitability despite challenging financial period

Despite the challenges faced in recent financial periods, Inotiv Inc, a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, is making strategic moves to improve its operations. Recently, the company announced its plan to insource its North American transportation operations in partnership with Vanguard Supply Chain Solutions LLC.
This decision comes at a time when Inotiv Inc has experienced a cumulative net loss of $-338 million in the 12-month period ending in the third quarter of 2023, resulting in a negative return on investment of -45.1%. In an effort to regain control and potentially reduce costs, the company aims to bring its tr...

A humbling three months by the company in the fourth quarter of 2023 earnings season

Inotiv, Inc. recently announced its plan to insource its North American transportation operations, which has raised concerns about the company's financial situation and its ability to generate positive returns. This decision comes after the company reported a significant net loss of $338 million during the 12-month period ending in the third quarter of 2023, leading to a negative return on investment of -45.1%.
By partnering with Vanguard Supply Chain Solutions LLC, Inotiv aims to bring its transportation operations in-house to gain better control and potentially save costs. However, it remains to be seen whether this move will yield the desired results, as the company has been struggling with declining...

Inotiv Inc's Robust Earnings Bolstered by $2.38 Million in Income Tax Provisions


As a financial analyst deeply involved in studying the most recent fiscal period of Inotiv Inc (NOTV), I am pleased to report that despite a decline in revenue, there are several positive indicators that point towards their ability to navigate the changing market landscape. Inotiv Inc, a leading player in the Medical Laboratories industry, has successfully turned a corner by converting a $0.15 deficit to earnings per share (EPS) of $0.07 per share in the third quarter of 2023.
While revenue fell by 8.802% to $157.47 million from $172.67 million in comparison to the same quarter the previous year, it is important to focus on NOTV's ability to adapt and generate income amidst challenging circumstances...

Inotiv Inc's Second Quarter of 2023 Reveals a Solid Top-line Surge, But Looming Losses Raise Investor Concerns

As an AI language model, my analysis is purely based on the data and information given. After evaluating the financial reports presented, it is apparent that Inotiv Inc has undergone a considerable setback in its financial performance for the span closing March 31, 2023. The firm's revenues have shown a slight improvement of 7.947%, standing at $151.46 million, compared to the same period the previous year, where the figures stood at $140.31 million. This increase represents a marginal boost that is not sufficient to cover the escalated losses incurred.
Moreover, despite improved EPS figures of $-3.41 per share at the end of the previous reporting season compared to -$3.39 in the latest period, it is ess...


Date modified: 2024-05-17T14:14:41+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com